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The Igκ locus undergoes a variety of different molecular processes during B cell devel-
opment, including V(D)J rearrangement and somatic hypermutations (SHM), which are
influenced by cis regulatory regions (RRs) within the locus. The Igκ locus includes three
characterized RRs termed the intronic (iEκ), 3′Eκ, and Ed enhancers. We had previously
noted that a region of DNA upstream of the iEκ and matrix attachment region (MAR) was
necessary for demethylation of the locus in cell culture. In this study, we further character-
ized this region, which we have termed Dm, for demethylation element. Pre-rearranged Igκ
transgenes containing a deletion of the entire Dm region, or of a Pax5-binding site within
the region, fail to undergo efficient CpG demethylation in mature B cells in vivo. Further-
more, we generated mice with a deletion of the full Dm region at the endogenous Igκ locus.
The most prominent phenotype of these mice is reduced SHM in germinal center B cells
in Peyer’s patches. In conclusion, we propose the Dm element as a novel Pax5-binding cis
regulatory element, which works in concert with the known enhancers, and plays a role in
Igκ demethylation and SHM.
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INTRODUCTION
The B cell receptors (BCRs) are encoded in the mouse genome
by the three immunoglobulin (Ig) loci, the IgH heavy chain locus,
and the two light chain loci, Igκ and Igλ. In their germline con-
formations, the Ig loci do not give rise to functional proteins.
It is only through a tightly regulated process of genome editing,
termed V(D)J recombination, that the loci are reconfigured to
allow transcription of an Ig gene in B cells. During the recom-
bination process, the variable (V), diversity (D), and joining (J)
segments are cleaved by the RAG complex and joined together
into one continuous segment by the DNA repair machinery (1).
Each rearrangement utilizes a single V, D (in the heavy chain), and
J segment, and each B cell contains one productively rearranged
heavy chain and light chain. In this way, B cells give rise to the
multitude of antigen recognition specificities which constitutes
the adaptive immune system.
The recombination of the different loci takes place in a devel-
opmentally staggered manner, with the IgH locus undergoing
VDJ recombination first in the pro-B cell stage (2). Light chain
rearrangement normally takes place only after a successful IgH
rearrangement, which allows the cells to differentiate to the pre-
B cell stage (3). In mice, the Igκ locus is the primary source for
the BCR light chain and will undergo preferential rearrangement.
The recombination of the different loci is kept tightly separated,
despite the fact that the enzymatic machinery responsible for the
processes is essentially the same and is present at both the pro-
and pre-B cell stages. The light chain loci are maintained in an
inaccessible chromatin state via epigenetic mechanisms prior to
the pre-B cell stage, at which point they become available to
the rearrangement machinery (3, 4). One such epigenetic mark
is DNA methylation, a mark that is established at the Igκ locus
during early embryonic development and which is hereditarily
maintained during cell division (5). DNA methylation has been
shown to block the activity of the rearrangement machinery
in vitro (6). The Igκ locus undergoes selective demethylation at
the pre-B cell stage, immediately prior to rearrangement (5, 7,
8). The rearranged Igκ allele is unmethylated from that stage
onward, while alleles which do not undergo rearrangement remain
methylated, even at the mature B cell stage. The low level of
methylation is significant for an additional stage of Igκ editing
during B cell development, namely for efficient somatic hypermu-
tation (SHM), which will allow affinity maturation of the BCR
in activated mature B cells (9). Methylated pre-rearranged Igκ
sequences do not undergo proper SHM at this stage, whereas
identical unmethylated sequences do (10).
The stage-specific transcription, rearrangement, and chro-
matin structure of the Igκ gene is mediated by regulatory sequences
within and in proximity to the locus. The locus contains three char-
acterized enhancers, including an intronic enhancer (iEκ) (11),
located in the intron between the Jκ segments and the Cκ exon
and two enhancers situated a few 1000 bases downstream of the
Cκ exon, termed 3′Eκ (12) and Ed (13). These enhancers work
in cooperation to promote stage-specific chromatin accessibility,
DNA demethylation, V to J rearrangement, heightened transcrip-
tion of the locus, and SHM in activated B cells, with different
enhancers contributing to a varying extent to each one of these
processes. iEκ and 3′Eκ have been implicated in promoting acces-
sibility and rearrangement of the locus in pre-B cells (14–16), while
3′Eκ and Ed strongly effect the level of transcription and SHM in
mature B cells (17, 18), neither of which is significantly affected by
the deletion of iEκ (14, 18). All of the three enhancers contribute
together to the demethylation of the locus (16, 19). Replacement
of iEκ with the IgH intronic µ enhancer is enough to change the
rearrangement timing of the locus to the earlier pro-B cell stage,
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showing that it is indeed these sequences which direct the temporal
precision of the developmental program (20).
Other than the enhancers, there are a number of additional
regulatory elements surrounding the Igκ locus, increasing the
complexity of the regulation. The recently discovered HS10 ele-
ment, which lies downstream of Ed, appears to mostly function
in plasma cells. While itself being a weak enhancer, HS10 acts as
a co-enhancer to strengthen the activities of 3′Eκ and Ed (21).
A matrix attachment region (MAR) lies immediately adjacent to
iEκ and mediates connections between the locus and the nuclear
matrix (22).
The activities of the cis regulatory elements are mediated by
various transcription factors, which either activate or repress the
enhancer activity. Many of these transcription factors are master
regulators of the B cell lineage, which are important for maintain-
ing B cell identity, such as E2A and PU.1 that bind sites in iEκ and
3′Eκ and substantially contribute to the enhancer activity (23–27).
However, binding of Pax5, a master regulator of B cell identity, has
been surprisingly missing from these enhancers in mature B cells.
While binding sites have been identified in 3′Eκ (24, 25, 28), as
well as in K-I and K-II (29, 30), which are regulatory regions (RR)
upstream of the Jκ segments, Pax5 plays an inhibitory role in this
context and is released during the pre-B cell stage when the locus
is activated. This is despite the fact that Pax5 itself is necessary for
the active induction of the locus (31).
In this work, we characterize a region adjacent to the MAR/iEκ
elements. We had previously identified this element as a partici-
pant in the demethylation process of the Igκ locus in cell culture
and thereby designated it Dm (32). Here, we find that this element
binds Pax5 in B cell stages from the pre-B cell stage and onward. It
is necessary for demethylation of a pre-rearranged Igκ transgene,
but deletion of the element in the endogenous locus does not affect
the demethylation process. We find that the element contributes
to efficient SHM of the Igκ locus, indicating that the Dm element
functions at more than one stage of B cell development.
MATERIALS AND METHODS
MICE
Targeted mice were backcrossed for 10 generations on a BALB/c
background. Igκ∆Dm/∆Dm mice were bred with wild-type (WT)
BALB/c to produce IgκWT/∆Dm mice. Human Cκ knock-in
mice (33) (gift from M. Nussenzweig) were bred with either
WT BALB/c or ∆Dm BALB/c to produce IgκWT/WTCκh/m and
IgκWT/∆DmCκh/m mice, respectively. IgκWT/∆Dm mice were bred
with CAST/EiJ (Cast) mice (Jackson Laboratory) to produce
BALB/c/Cast IgκWT/WT and BALB/c/Cast Igκ∆Dm/WT/littermates.
Rag1-/- mice (Jackson Laboratories) were bred onto a Cast back-
ground. Igκ∆Dm/∆Dm were bred onto a C57BL/6 Rag1-/- (B6) back-
ground containing the 3H9 IgH chain transgene (IgH+). CAST/EiJ
Rag1-/- mice were bred with C57BL/6 Rag1-/- IgH+ either with
or without a deletion of the Dm element, giving rise to B6/Cast
Rag1-/- IgH+ Igκ∆Dm/WT and B6/Cast Rag1-/- IgH+ IgκWT/WT
mice, respectively. Mice were housed in specific pathogen-free con-
ditions at the Hebrew University Medical School animal facility.
Transgenic mouse lines Lκ, Lκ∆Dm, and Lκ∆70 were produced,
using the constructs described in the Section “Targeting Con-
structs,”at the Hadassah Hospital Medical School Transgenic Unit.
Two independent founder lines were produced for the Lκ trans-
gene, four for the Lκ∆Dm and three for the Lκ∆70. The copy
number of the transgene for each founder line varied from low
(two insertions) to high (20 insertions) with most lines having
a moderate number of insertions (four to eight insertions). All
animal procedures were approved by the Animal Care and Use
Committee of the Hebrew University of Jerusalem.
TARGETING CONSTRUCTS
The Lκ∆Dm construct was prepared using the following steps;
the 4.3-kb KpnI–KpnI fragment, containing VκJ5–Cκ sequence,
was excised from the Lκ plasmid (34) and cloned into the KpnI
site of the Bluescript vector which was modified to destroy the
polylinker XbaI site. The resulting pBSKpn2 plasmid was cut at
unique compatible XbaI and NsiI sites, and recirculized, resulting
in the deletion of 930 bp XbaI–NsiI Dm fragment from the JκCκ
intron. The KpnI–KpnI Dm-deleted fragment was excised and
reinserted into the Lκ plasmid, resulting in the Lκ∆Dm construct.
The Lκ∆70 construct was prepared using the following steps;
the HindIII-blunt TaqI 2.6-kb fragment, containing the germline
Jκ region, was cloned to HindIII–EcoRV sites of the Bluescript
vector. Next, a blunted Bst EII–BglII 2-kb fragment containing the
Cκ exon was cloned into blunted EcoRI–BamHI sites of the previ-
ously described Jκ containing Bluescript vector to yield the p-∆70
construct, which had the 70 bp TaqI–Bst EII deletion introduced
into the HindIII/BglII 5.6-kb JκCκ germline sequence. The 1-kb
intact intronic XbaI–HindIII region of pBSKpn2 plasmid (pre-
viously described, containing the KpnI–KpnI fragment from the
Lκ plasmid) was replaced with XbaI–HindIII fragment bearing
the 70 bp deletion, excised from p-∆70. The 4.2-kb KpnI–KpnI
fragment with the 70 bp deletion was excised from the result-
ing pBSKpn2 ∆70 plasmid and cloned back into the Lκ plasmid,
replacing the original 4.3-kb KpnI–KpnI sequence, and yielding
the Lκ∆70 construct.
The∆Dm targeting vector was prepared as using the following
steps; a short arm of homology (neo-SAH) plasmid was con-
structed by using BanII (ends filled with Klenow) and NsiI to
excise the 1.25-kb MAR and Eiκ containing fragment from the
pBκMAR plasmid. This fragment was cloned into the sticky XbaI
and blunted Pst I sites of the Bluescript vector. This construct
was next cut at the polylinker sites ClaI and EcoRI and used for
insertion of the 1.26-kb Not I–XbaI loxP flanked neoR gene frag-
ment from the pMMneoflox-8 plasmid (all restriction ends were
made blunt by reaction with the Klenow fragment), a long arm
of homology (TK-LAH) plasmid was constructed by excision of
the 7.1-kb Pst I–Pst I germline Jκ–Cκ region containing fragment
from pSPIg8 plasmid (ends were blunted by reaction with T4 poly-
merase) and ligation into the HindIII site (blunted with reaction
with Klenow fragment) of pIC19R/MC1-TK. The final ∆Dm tar-
geting vector was produced by cloning of the 8.9-kb XhoI–SalI
fragment from TK-LAH into the neo-SAH SalI polylinker site.
Targeting strategy is illustrated in Figure S1 in Supplementary
Material.
CELLS AND CULTURES
All cells in this manuscript were grown in RPMI 1640
medium (Gibco) supplemented with 10% fetal calf serum, 2 mM
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l-Glutamine, 100µg/ml penicillin, 100µg/ml streptomycin, and
50µM 2-mercaptoethanol. BaF3 cell medium was addition-
ally supplemented with IL3 secreted by WEHI-3b cells. IL-7-
dependent pre-B cell cultures used for chromatin immunopre-
cipitation (ChIP) analysis were performed as has been previously
described (35). COP8 cells were transiently transfected with a
Pax5 expression plasmid (gift from M. Busslinger) using the DEAE
dextran method (36).
ISOLATION AND ANALYSIS OF LYMPHOID CELLS FROM BONE
MARROW AND SPLEEN
Bone marrow cells from femur and tibia bones were flushed out
with PBS using a 25 G syringe needle. Spleens were disrupted and
pulp dispersed in PBS. Erythrocytes were lysed with RBC lysis
solution (Biological industries) and cells were washed. When indi-
cated, cells were isolated on magnetic MACS columns (Miltenyi
Biotech) by positive selection with either αCD19 magnetic beads
or streptavidin magnetic beads and biotinylated αB220 (Miltenyi
Biotech), according to the manufacturer’s instructions. Cell purity
following isolation was assayed as <95% by flow cytometry (LSR
II, BD Bioscience).
Cells from erythrocyte disrupted spleens and bone marrows
were stained with the antibodies indicated and cellular com-
position was analyzed by flow cytometry (LSR II, BD Bio-
science). The antibodies used in this report include anti-mouse-
Igκ-PE (Southern Biotech), anti-human-Igκ-FITC (Southern
Biotech), anti-IgM-APC (eBioscience), anti-B220-PerCP-Cy5.5
(Biolegend), anti-CD43-PE (Biolegend), anti-IgD-FITC (eBio-
science). Flow cytometry output was analyzed using Flowing
Software v2.5.0 (Turku Centre for Biotechnology).
ANALYSIS OF DNA METHYLATION BY SOUTHERN HYBRIDIZATION
Cellular genomic DNA (5–15µg) was digested with the spec-
ified enzymes, electrophoresed in native (Tris–acetate) agarose
gels, denatured and transferred to nitrocellulose. DNA was then
hybridized with the specific radioactive probes and analyzed by
autoradiography (37). Hybridization was carried out at 65°C for
16 h. The degree of methylation was measured semiquantitatively
using a PhosphorImager BAS-1800 (Fuji) and Tina2.10 g software
(IsotopenMedgerate GmbH).
NUCLEAR EXTRACT PREPARATION
Cells (3–5× 106) were washed in PBS, resuspended in low salt
buffer (10 mM HEPES pH 7.9, 10 mM KCl, 0.1 mM EDTA, 0.1 mM
EGTA, 1 mM DTT, 0.5 mM PMSF, 20µg/ml aprotinin, 10µg/ml
leupeptin) and incubated for 10 min on ice. NP-40 was then
added to a final concentration of 0.66%, the mixture was vor-
texed briefly and centrifuged for 30 s, 16,000 g. Nuclei were resus-
pended in high salt buffer (20 mM HEPES pH 7.9, 0.4 mM KCl,
1 mM EDTA, 1 mM EGTA, 1 mM DTT, 1 mM PMSF, 20µg/ml
aprotinin, 10µg/ml leupeptin) and rotated for 20 min at 4°C.
Nuclear debris was removed by centrifugation at 16,000 g for
20 min at 4°C.
ELECTROPHORETIC MOBILITY SHIFT ASSAY
Oligonucleotide probes were end-labeled with α32P-dCTP using
Klenow fragment. Two micrograms of nuclear extract was
incubated with 0.3 ng of the radioactive double strand probe
in a solution containing 2µg poly-dI-dC, 10 mM Tris–HCl pH
7.9, 10% glycerol, 100 mM KCl, and 4 mM DTT for 20 min at
25°C. In competition assay, 100-fold molar excess of an unlabeled
probe was preincubated for 10 min prior to the addition of the
radiolabeled probe. In supershift assays, the indicated antisera
(antibodies A1 and A2 kindly provided by Meinrad Busslinger)
were added to the nuclear extract 15 min prior to the addi-
tion of the probe. Samples were then electrophoresed at room
temperature on a 4% polyacrylamide gel (19:1 acrylamide/bis)
in 0.25× TBE buffer. Gels were dried and bands were visual-
ized by autoradiography. Probes used for assays were Dm-70 bp
5′-CGATTGTAATTTTATATCGCCAGCAATGGACTGAAACGGT
CCGCAACCTCTTCTTTACAACTGGGTGAC-3′ and the Pax5-
binding site from the promoter of sea urchin H2a-2.2 5′-GGG
TTGTGACGCAGCGGTGGGTGACGACTCCAGAGTCGACA-3′.
DNAse I FOOTPRINTING
TaqI–SacII fragment (130 bp) from the Dm segment, encompass-
ing the detected Pax5-binding site, was labeled with 32P-dCTP
at TaqI end by a fill-in reaction with Klenow fragment to a
specific activity greater than 104 cpm/ng of DNA. Probes were
incubated for 20 min at room temperature with 20µg of nuclear
extract in a 50-µl reaction mixture containing 10 mM Tris pH 7.8,
14% glycerol, 57 mM KCl, 4 mM DTT, and 0.2µg poly(dI-dC).
DNase I (0.5–1 U; Promega) diluted in 50 mM MgCl2, 10 mM
CaCl2 was added for 1 min. The reaction was terminated by
addition of 150µl of a stop solution containing 200 mM NaCl,
20 mM EDTA, 1% SDS, and 5µg yeast tRNA. DNA was extracted
with phenol–chloroform, ethanol precipitated, dissolved in load-
ing buffer (deionized Formamide – 5 mM EDTA), denatured for
10 min at 85°C and separated on a 6% polyacrylamide sequenc-
ing gel containing 7 M urea. Sequencing reactions performed
using the Maxam and Gilbert procedure were run parallel to
each probe.
BISULFITE SEQUENCING
DNA was converted by bisulfite treatment using the EpiTect Bisul-
fite kit (Qiagen) and amplified by PCR with GoTaq (Promega)
using the following primers; BisDm F 5′-TTGATAGATAGTTTAA
GGGGTTTTT-3′, BisDm R 5′-ATCTATCACATCTCTATTCTCTT
CAAATTA-3′, BisJκ2 F 5′-TTTTTGGAGAATGAATGTTAGTGTA
ATAAT-3′, BisJκ2 R 5′-TAAAACAATTTTCCCTCCTTAACAC-3′;
ionJκ2 F 5′-(ion torrent A adapter)-(index)-GAAATGTTTAAAGA
AGTAGGGTAGTTTGT-3′; ionJκ2 R 5′-(ion torrent P1 adapter)-
CCCTCCTTAACACCTAATCTAAAAATAA-3′; ionJκ4 F 5′-(ion
torrent A adapter)-(index)-ACCAAAAATAACTCATTTAACCAA
AATAT-3′, ionJκ4R 5′-(ion torrent P1 adapter)-TGATTTTATGTT
AGATTTGTGGGAR-3′. Amplicons were visualized on a 1.5%
agarose gel, excised, and purified with the Qiaquick gel extraction
kit (Qiagen). Amplicons intended for standard Sanger sequencing
were TA cloned using pGEM-T easy kit (Promega). PCR with uni-
versal T7 and SP6 primers was performed on transformed colonies
and correctly inserted clonal amplicons were sequenced by Sanger
sequencing (ABI-Prism-3700). Samples amplified with ion tor-
rent fusion primers were sequenced on an Ion Torrent Personal
Genome machine (Invitrogen).
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CHROMATIN IMMUNOPRECIPITATION
IL-7-dependent pre-B cell cultures were made from the bone mar-
row of IgκWT/∆Dm mice as has been previously described (35).
Cells were crosslinked with formaldehyde, chromatin extracted,
and immunoprecipitated with an antibody directed against Pax5
(5µg per 30µg DNA) (SantaCruz). Semi-quantitative PCR
was carried out on input DNA compared to immunoprecip-
itated DNA using primers specific for the Dm element and
primers spanning the Dm deletion in order to test the enrich-
ment on the WT and ∆Dm alleles separately. PCR amplicons
were visualized on an 8% polyacrylamide gel. Primers used:
∆DmChIP-F 5′-CCAAGAGATTGGATCGGAGA-3′, ∆DmChIP-
R 5′-CCATGACTTTTGCTGGCTGT-3′; WTDmChIP-F 5′-GGCC
ACGGTTTTGTAAGACA-3′, WTDmChIP–R 5′-CAGGGTGAA
CGCCAAATG-3′, CD19-F 5′-GATTTGGAAGAGTGCCTACA-3′,
CD19-R 5′-GCCTGCCTCCTACTAAGGTA-3′, β-actin-F 5′-CG
CCATGGATGACGATATCG-3′, β-actin-R 5′-CGAAGCCGGCTT
TGCACATG-3′.
SOMATIC HYPERMUTATION ANALYSIS OF PEYER’S PATCHES B CELLS
Peyer’s patches (PP) were dissected from the small intestines of
4–6-month-old IgκWT/WT, Igκ∆Dm/∆Dm, or IgκWT/∆Dm mice. PP
from three to four mice were pooled for each experiment. PP were
mashed through a 70µm nylon mesh and washed with PBS to
produce single cell suspensions. Cells were washed with PBS-0.5%
BSA and labeled with PNA-FITC (Vector Labs) and αB220-PE
(BD Bioscience). Germinal center B220+/PNAhigh B cells were
sorted (FACSStar BD) to greater than 90% purity. WT and ∆Dm
rearranged Igκ alleles were amplified with Vκ-Degenerate 5′-
GTCCCTGCCAGGTTYAGTGGCAGTGGRTCWRGGAC-3′ and
R3-1 5′-CAGACCCTGGTCTAATGGTTTGTAACCACATGGG-3′
primers using high fidelity PCR kit (Roche) with an initial denat-
uration of 4 min at 94°C, followed by 35 cycles of denaturation
at 94°C for 15 s and annealing combined with elongation at 68°C
for 2 min. 3′ A-overhang nucleotides were added by 20 min incu-
bation with Taq polymerase and ATP at 72°C. PCR fragments
corresponding to Vκ–Jκ5 rearrangement of the WT and ∆DM
(2.2 and 1.3 kb, respectively) were visualized on a 0.8% agarose
gel, excised and purified with the QIAquick gel extraction kit
and cloned into the TOPO-2.1 TA cloning vector (Invitrogen).
Plasmids from single colonies were prepared and sequenced by
Sanger sequencing (ABI-Prism-3700). Sequences were aligned to
the Igκ locus and mutations in the 188 bp region downstream of
the Vκ–Jκ5 joint were analyzed.
PYROSEQUENCING
RNA was extracted using tri-reagent (Sigma-Aldrich) from
CD19+ MACS sorted (Miltenyi Biotec) splenic cells of
BALB/c/Cast IgκWT/WT and BALB/c/Cast Igκ∆Dm/WT littermates,
as well as control BALB/c and Cast mice. cDNA was prepared
with mMLV reverse transcriptase (Promega) using random hexa-
mer primers (Thermo Scientific). Rearranged Igκ transcripts were
amplified with Vκ-degenerate: 5′-GTCCCTGCCAGGTTYAGT
GGCAGTGGRTCWRGGAC-3′ and biotinylated CκR-5′-GGGAA
GCCTCCAAGACCTTA-3′. Resulting amplicons were visual-
ized on a 1.5% agarose gel, excised and purified with the
QIAquick gel extraction kit (Qiagen). Allelic distribution of
BALB/c/Cast transcripts was assessed by pyrosequencing on
a PyroMark Q24 instrument (Qiagen) using Cκ-pyro primer
5′-ACATCAACTTCACCCAT-3′.
LUCIFERASE REPORTER ASSAY
M12 cells were transiently transfected using the DEAE dextran
method (36) with a luciferase reporter plasmid containing the
minimal β-globin promoter TATA box (pTATA), without any addi-
tional regulatory elements or with insertions of the Dm element,
iEκ, or four NF-κB binding sites immediately upstream of the
promoter. The cells were co-transfected with pβ-GAL to normal-
ize for transfection efficiency. Luciferase activity was measured
using the Luciferase Assay System (Promega) according to the
manufacturer’s instructions.
RESULTS
CHARACTERIZATION OF THE Dm ELEMENT
We have previously identified an element lying ~700 bp upstream
of the iEκ which facilitates demethylation of the Igκ locus in cell
culture, in cooperation with iEκ (32). The element, designated
Dm, is not part of the previously defined core iEκ (Figure 1A). The
Dm element, as determined by our previous experiments, spans
~1 kb and contains numerous areas which are conserved through-
out different species (Figure 1A). The element itself contains a
stretch of ~200 bp with the highest density of CpG sites found
within the Igκ locus. In order to see whether this element was
transcriptionally active, we tested its functionality in an enhancer
reporter assay. We compared its activity in a reporter plasmid to the
well-characterized iEκ (Figure 1B). Luciferase assays show that the
Dm element acts only as a weak transcriptional enhancer which
is about sevenfold weaker than the core intronic enhancer in M12
B cell lymphoma cells (Figure 1C), suggesting that the Dm ele-
ment on its own does not exert its effect by direct transcriptional
activation.
Pax5 BINDING AT THE Dm ELEMENT
Cis regulatory elements, such as enhancers and promoters, convey
their influence on cellular phenotypes by binding trans regulatory
transcription factors, which mediate transcription and changes
in chromatin structure. As the Igκ locus is selectively active in B
cells, starting from the pre-B cell stage, we speculated that the Dm
element may bind B cell-specific transcription factors, thus medi-
ating the changes it induces. Upon searching for potential binding
sites for key B cell transcription regulators, we identified an area
within the CpG-rich segment with remarkable similarity to the
Pax5 consensus sequence (38) (Figure 2A). A 70-bp probe contain-
ing this sequence is shifted to a specific height when incubated with
nuclear extracts from B lineage cells which have passed the pro-B
cell stage, but not in other cell types tested in an electro-mobility
shift assay (EMSA) (Figure 2B). These results clearly show that
the binding of this protein is specific for the stages when the Igκ
locus is active. Notably, this specific shift can be attained using a
fibroblast extract, which normally does not produce such a shift,
by forced expression of Pax5 (Figure 2C), and titrated away by
competition with a probe containing the Pax5-binding site of the
H2a-2.2 promoter, strongly implying that indeed the Pax5 pro-
tein is binding at this site. When the nuclear extract is incubated
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FIGURE 1 | Conservation and transcriptional activity of the Dm element.
(A) Schematic map of the Igκ locus, drawn to scale. Basewise conservation
across mammalian genomes is shown graphically, adapted from UCSC
genome browser “Conservation” track. (B) Schematic map of transfected
plasmid constructs. (C) Average relative luciferase activity in M12 cells
transfected with the indicated plasmids. Plasmids were co-transfected with a
constitutive β-Gal-expressing plasmid and luciferase activity was normalized
for transfection efficiency to β-Gal activity. Transfection and luciferase assay
was carried out at least three times for each construct. Error bars represent
the standard deviation of the luciferase activity.
with an antibody raised against the DNA-binding domain of Pax5
(designated A1), the shift on the EMSA gel disappears, whereas
incubation with an antibody recognizing the Pax5 transactiva-
tion domain (designated A2) introduces a supershift, confirming
that the 70-bp probe indeed specifically binds the Pax5 transcrip-
tion factor (Figure 2D). DNase I footprinting using nuclei of the
Pax5-expressing M12 B cell lymphoma cell line shows a defini-
tive protection at the putative Pax5-binding site in comparison to
S194 plasmacytoma cells which do not express Pax5 (Figure 2E).
Interestingly, this specific footprint correlates precisely with the
predicted Pax5-binding site. ChIP was performed on pre-B cells
from IgκWT/∆Dm mice (introduction of the∆Dm allele into mice is
described in Section Characterization of Methylation, Rearrange-
ment and B Cell Development in Dm Knockout Mice) with an
antibody recognizing the Pax5 protein. While the Dm positive
allele showed significant enrichment for Pax5, the deleted allele was
not enriched for Pax5-binding (Figure 2F). These results indicate
that Pax5 indeed binds in this region in vivo and that the binding is
directly dependent on the presence of the Dm element. Altogether,
the above described data shows that Pax5 specifically binds to the
Dm element in vivo.
Dm FACILITATES DNA DEMETHYLATION OF Igκ TRANSGENES
We wished to further investigate the role of the Dm element in
demethylation of the Igκ locus. In order to do so, we introduced a
well-characterized transgene (34, 39) containing a pre-rearranged
Igκ allele to mice, termed Lκ (Figure 3A). Two additional trans-
genic mice were produced with modified constructs, one contain-
ing a deletion of the entire Dm locus, termed Lκ∆Dm, and the
second containing a deletion of the 70 bp region containing the
Pax5-binding site, termed Lκ∆70 (Figure 3A). DNA from splenic
B220+ cells was assayed for the methylation of these transgenes
by restriction analysis, which allows for simple differentiation
between the transgenic and endogenous regions. Digestion with
KpnI gave rise to a 4.3-kb fragment in the Lκ and Lκ∆70 trans-
genes and a 3.4-kb fragment in the Lκ∆Dm transgene, whereas the
endogenous locus yields a 15-kb fragment. These fragments were
further digested with methylation-sensitive restriction enzymes
AciI and HhaI (HhaI was not used to assess the Lκ∆Dm state since
the HhaI site is deleted in this transgene). The digested DNA was
hybridized with a probe recognizing the MAR and iEκ sequences.
To assess the level of methylation, the amount of the undigested
DNA was measured using a PhosphorImager. Interestingly, while
the Lκ transgene was almost completely unmethylated, with only
8% of the DNA remaining undigested (Figures 3B,C), the Lκ∆Dm
transgene was highly methylated (73%) (Figures 3B,D), indicat-
ing that indeed the Dm element facilitates the hypomethylation of
the Igκ locus in B cells. Notably, deletion of only 70 bp from the
Dm in the Lκ∆70 transgene reduced the ability of the transgene
to become unmethylated (50%) (Figures 3C,D).
Bisulfite analysis of the CpG-rich region surrounding the Pax5-
binding site in the endogenous locus, Lκ and Lκ∆70 transgenes
showed a picture that agrees quite nicely with the above results
(the Lκ∆Dm was not assayed in this manner, since this region is
deleted within the transgene). These results take into considera-
tion the difference between the methylation levels measured by
bisulfite sequencing, which probes all CpG sites in the region, and
the restriction analysis which measures the methylation only at
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FIGURE 2 | Pax5-binding within the Dm element. (A) Comparison of the
putative Pax5-binding site within the Dm element, known Pax5-binding site
in sea urchin H2a-2.2 promoter and Pax5 consensus sequence. Bases which
match the consensus sequence are marked in red, while bases which do not
match are marked in gray. (B) Electro-mobility shift assay (EMSA) of
TaqI–BstEII 70 bp fragment from the Dm element, containing the putative
Pax5-binding site, with the indicated hematopoietic cell type nuclear
extracts. Red arrowhead indicates B cell lineage-specific shift.
(C) Competition EMSA. Unlabeled H2a-2.2 probe competes with radioactive
TaqI–BstEII Dm probe and reduces shift in B lineage cell extracts (M12,
70Z/3), and in extracts of fibroblast cells (cop8) transfected with a Pax5
expression vector. Nonsense unlabeled probe (ns) is unable to compete with
Dm probe. Red arrowhead indicates specific shift. (D) Supershift assay with
TaqI–BstEII Dm probe, which was incubated with antibodies (ab) raised
against the DNA-binding site of Pax5 (A1), the transactivation domain (A2),
or general rabbit antisera (P.I.). (E) DNase I footprinting assay on end-labeled
TaqI–SacII probe from the Dm element. Labeled probe was incubated with
nuclear extracts from the indicated cell types. A control Maxam and Gilbert
reaction (G/A) was run in parallel. Footprint specific to Pax5-expressing M12
cells is indicated with a red arrow. Location of the putative Pax5-binding site
is marked in red on the nucleotide sequence. (F) Chromatin
immunoprecipitation (ChIP) enrichment of Pax5 at the Dm element in
Igκwt/∆Dm cultured pre-B cells. Enrichment was measured by
semi-quantitative PCR via comparison of the input DNA (Input) to the
immunoprecipitated fraction (αPax5), using primers specific to the Dm
element (Dm) and the deleted allele (∆Dm). One and three times the
amount of PCR template were run in parallel to ensure linearity. Positive
(CD19 promoter) and negative (β-actin promoter) controls for Pax5-binding
were analyzed in parallel to ensure specificity of the enrichment. ChIP with a
non-specific antibody (IgG) does not enrich the Dm element.
the sites which correspond to the digestion site. The endogenous
locus is close to 50% methylated, as expected from a region which
undergoes monoallelic demethylation (Figure 3E). The Lκ∆70
transgene is 76% methylated, while the Lκ transgene is completely
unmethylated (Figure 3E). In order to see how these results cor-
relate with the restriction analysis, the percent of sequences which
would be protected from AciI digestion was assessed. Fifty-seven
percent of the Lκ∆70 sequences remain protected, supporting the
restriction analysis results. These experiments clearly show that
the Dm element contributes to the demethylation of the Igκ locus
in vivo, results that support previously published data obtained
from cell culture systems.
CHARACTERIZATION OF METHYLATION, REARRANGEMENT, AND B
CELL DEVELOPMENT IN Dm KNOCKOUT MICE
Given the results in transgenic mice, we generated a knockout
mouse in which the entire Dm element in the endogenous locus
was replaced with a LoxP-flanked Neo gene which was then excised
from the genome (Figure 4A; Figure S1 in Supplementary Mate-
rial). We assessed the methylation pattern of the Igκ locus by
Frontiers in Immunology | B Cell Biology May 2014 | Volume 5 | Article 240 | 6
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Levin-Klein et al. A novel Igκ regulatory element
FIGURE 3 | Effect of Dm element on methylation of Igκ locus in
transgenic mice. (A) Schematic map of the transgenes and probe used
in experiments. Bold Aci I line indicates multiple Aci I restriction sites
within close proximity. (B,C) Southern blot assay assessing methylation
state of Lκ, Lκ∆Dm (B) and Lκ∆70 (C) transgenes in B220+ splenic B
cells. DNA was digested with KpnI either alone or with methylation
sensitive enzymes Aci I or HhaI and hybridized with the indicated probe.
Methylation levels were quantified by phosphorImager. (D) Graphical
representation of the average methylation levels at Aci I sites of the
indicated transgenes, as quantified by phosphorImager. Methylation was
measured in DNA from two to four independent founder mice for each
transgene. Error bars represent standard deviation of the methylation
levels. (E) Bisulfite analysis of CpGs flanking the Pax5-binding sequence
of the Dm element. Triangles mark CpGs recognized by Aci I restriction
enzyme. Black circles signify methylated, white signify unmethylated,
gray signify undetermined, and red signify CpGs deleted in transgene.
Percentage of methylated CpGs is noted. Relative location of the CpGs
within the Dm element is indicated with arrows on schematic
representation of the genomic region. Location of primers is marked by
arrows in (A).
bisulfite analysis of the Jκ2 fragment in ex vivo mature B cells.
Surprisingly, given the strong phenotype in transgenic mice, no
significant difference was seen between the methylation levels of
IgκWT/WT and Igκ∆Dm/∆Dm mice (Figure 4B).
We then proceeded to investigate whether the methylation pat-
terns at the Igκ locus are affected by deletion of the Dm element in
the pre-B cell stage, which is the very first stage in which demethy-
lation of the locus is detected. To this end, Igκ∆Dm mice were
bred onto a Rag1−/− background, effectively blocking rearrange-
ment of the Igκ locus and differentiation to the mature B cell stage.
Expression of a pre-rearranged IgH transgene was ensured in order
to allow the cells to express the pre-BCR and differentiate to the
pre-B cell stage. These mice were further bred with Rag1−/− M.
castaneous mice, which contain an intact Dm element, thus allow-
ing distinction between the WT and the Dm-deleted alleles based
on the strain-specific DNA polymorphisms. Ex vivo CD19+ bone
marrow cells were purified from B6/Cast Rag1-/- IgH+ Igκ∆Dm/WT
and B6/Cast Rag1-/- IgH+ IgκWT/WT mice and the methylation of
the Jκ2 and Jκ4 segments was determined by high-throughput
sequencing. We did not, however, detect significant differences in
levels of methylation between the WT and∆Dm alleles (Figure 4C,
Figure S2 in Supplementary Material). Taken together,we find that,
while the Dm element plays a role in demethylation of the Igκ locus
in transgenes, this role is not translated to the endogenous locus,
probably due to redundancy of the many enhancers of the locus,
not all of which are present in the transgene.
We explored the possibility that the Dm element may affect
other developmental processes pertaining the Igκ locus and nor-
mal B cell development, as has been observed for cis regulatory
elements in the locus such as the enhancers. There was no sig-
nificant difference seen in the levels of rearrangement of the
WT versus ∆Dm allele, as assessed by FACS and pyrosequencing
analyses (Figure S3 in Supplementary Material). The pyrosequenc-
ing results also indicate that the level of Igκ transcription is not
changed by the deletion of the Dm element, supporting the above
described results showing that the Dm element is a weak tran-
scriptional enhancer. The B cell development in the bone marrow
of Igκ∆Dm/∆Dm mice appeared normal, with proportions of pro-,
pre-, immature, and mature B cells similar to those of WT mice
(Figure 4D, Figure S4 in Supplementary Material). Overall, these
results indicate that, in the endogenous locus, deletion of the Dm
element does not curtail these early stages of B cell development.
EFFECT OF Dm ELEMENT ON SHM
We investigated whether deletion of the Dm element affects a later
stage of Igκ maturation, specifically the process of SHM in acti-
vated B cells. Levels of SHM in IgκWT/WT mice versus Igκ∆Dm/∆Dm
mice were examined, and a significant drop in amount of muta-
tions in the germinal center B220+PNAhigh B cells from Peyer’s
patches of the Dm negative mice was observed (Figures 5A,B). In
order to rule out mouse to mouse variation, which could poten-
tially give rise to such an effect, SHM in heterozygous IgκWT/∆Dm
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FIGURE 4 | Effect of deletion of the Dm element at the endogenous locus
on Igκ methylation and B cell development in the bone marrow.
(A) Schematic map of the endogenous Igκ locus in wild-type (WT) and Dm
knockout (∆Dm) mice. Relative locations of CpGs in Jκ2 region are indicated
with arrows. CpG present only in Castaneous (Cast) strain is marked with a
red arrow. (B) Bisulfite analysis of CpGs at the Jκ2 region in splenic CD19+ B
cells from WT and ∆Dm mice. Black circles signify methylated CpGs, white
circles signify unmethylated CpGs. Percentage of methylated CpGs is noted.
(C) Bisulfite analysis by high-throughput sequencing of Jκ2 region from
CD19+ bone marrow pre-B cells from Rag1−/− C57BL/6/Castaneous
IgH-3H9-Tg mice with or without a deletion of the Dm element on the
C57BL/6 (B6) allele. Copies (1600–3000) of each CpG from each genotype
were analyzed. Alleles were differentiated by strain-specific polymorphic sites
within the amplified regions. The methylation state of each CpG is
summarized graphically. (D) Summary of proportions of B cell populations
within bone marrows of WT and ∆Dm mice. Error bars mark standard
deviation. Six mice were analyzed in each group. Representative FACS plots
can be seen in Figure S4 in Supplementary Material.
mice was assessed. Here too, the proportion of mutations on
the ∆Dm allele was lower than on the WT allele (Figure 5C).
As a control, a similar number of colonies were sequenced from
B220+PNAlow cells, with no mutations detected (data not shown).
While the average number of mutations is lower in the∆Dm allele,
sequences which have undergone SHM do so at an efficiency sim-
ilar to the WT allele, as seen when examining the mutation rate
in total sequences versus rate in mutated sequences (Figure 5),
suggesting that the Dm element affects the recruitment but not
the processivity of the machinery involved in SHM. These results
indicate that the Dm element, which is immediately adjacent to
the intronic MAR and iEκ, helps promote SHM. This is particu-
larly notable, as deletion of the MAR/iEκ region on its own has no
discernable effect on the normal SHM process (18). Our results
clearly show that the Dm element contributes to proper SHM at
the Igκ locus, a role which has not been previously attributed to
the intronic enhancer region.
DISCUSSION
In this paper, we characterized a novel cis regulatory element sit-
uated within the Jκ–Cκ intron of the Igκ locus. This sequence
was originally identified as an element which lies adjacent to iEκ
and contributes to its demethylating activity, as deletion of either
element was sufficient to abolish demethylation in a cell culture
system (32). In our present study, we find that the Dm element is
necessary for hypomethylation of the Igκ locus of the Lκ transgene
in vivo, but is dispensable for the demethylation of the endogenous
locus. The apparent discrepancy between the phenotype in these
two cases may be due to the fact that the transgene contains the
sequences in the Igκ locus up to the 3′Eκ, but does not include the
Ed. The three Igκ enhancers work cooperatively and, to a certain
extent, redundantly to activate and demethylate the locus. Previous
studies have shown that deletion of any single enhancer has only
a small effect on the developmentally regulated DNA demethyla-
tion, whereas the combined lack of two enhancers abolishes the
demethylation process (16, 19). Another difference between the
transgene and the endogenous locus is that the transgene contains
a pre-rearranged Igκ. It is possible that the Dm element only affects
the demethylation when the locus is in a rearranged configuration,
but not in the germline conformation. In this study, we see that
the deletion of the Dm sequence, which is not part of the core
iEκ, greatly impedes the demethylation process in the transgene,
indicating that the Dm element contributes to the activity of iEκ,
possibly as a co-enhancer. As the Dm is only a weak transcrip-
tional enhancer as a solitary element, it is the combined activity
with neighboring cis acting elements which gives rise to the full
activity.
The mechanisms by which genomic loci undergo targeted
demethylation have long been shrouded in mystery (40). Findings
from recent years have pointed to the Tet family of enzymes as
Frontiers in Immunology | B Cell Biology May 2014 | Volume 5 | Article 240 | 8
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Levin-Klein et al. A novel Igκ regulatory element
FIGURE 5 | Effect of deletion of the Dm element at the
endogenous locus on somatic hypermutations. Somatic
hypermutations in B220+PNAhigh Peyer’s patches germinal center B
cells from (A) IgκWT/WT, (B) Igκ∆Dm/∆Dm, and (C) IgκWT/∆Dm mice. Pie charts
indicate the number of mutations sequenced in a 188-bp region
immediately downstream of the Vκ–Jκ5 joint. Number of colonies
sequenced from each mouse and mutation rate per kilobase in total
and mutated clones are indicated.
possible catalysts of the demethylation process, via oxidation of
the methyl group into a hydroxymethyl moiety (41). When acting
as a demethylation intermediate, the hydroxymethylated cytosine
is then either passively diluted during DNA replication (42), as it
is not recognized by the methylation maintenance machinery (43,
44),or, conversely, is actively excised from the genome and replaced
with an unmethylated nucleotide (45,46). Targeting of Tet proteins
to specific genomic loci is sufficient to induce local demethylation
(47, 48). Tet2 has been implicated in the active demethylation of
tissue-specific genes in postmitotic human monocytes (49). Addi-
tionally, Tet2 has been found to bind PU.1 (50) and EBF1 (51) in
the hematopoietic system. A recent report has uncovered a dif-
ferent strategy to induce demethylation by which DNMT1, the
maintenance DNA methyltransferase, is sequestered from specific
genomic loci by binding non-coding RNA. This prevents the place-
ment of methyl groups on DNA during replication and, in turn,
brings about passive demethylation of a defined region (52). It is
still unclear what mechanism is implemented by the cis regulatory
elements to demethylate the Igκ locus during B cell development,
especially since deletion of Tet2, the strongest Tet candidate in the
immune system, causes leukemia in mice (53–55), which masks
many of the tissue-specific effects that may occur as a result. As
methylation is a strong barrier to the rearrangement process (8),
future studies can address this issue.
We have identified a sequence within the Dm element which
binds the B cell lineage specifier Pax5. This site is bound by Pax5
starting with the pre-B cell stage, up to mature B cells, but is
unbound in Baf3 pro-B cells,where the Igκ locus is not yet activated
and made accessible for rearrangement, nor in plasma cells where
Pax5 expression is down-regulated. It should be noted, though,
that the Baf3 pro-B cell line tested here does not express Pax5 (56),
whereas most pro-B cells do, and as such we are unable to rule
out the possibility that Pax5 is already bound at the pro-B cell
stage. This is the first report, to our knowledge, of a Pax5-binding
site within the Igκ locus which binds Pax5 at the time of locus
activation. Previous reports have located sites in 3′Eκ (24) and
in the K-I–K-II (29, 30) regulatory elements in which Pax5 plays
a repressive role and where binding is lost upon Igκ locus activa-
tion. The new site we report is particularly interesting, considering
that Pax5 is known to be directly necessary for Igκ locus activa-
tion and κ0 germline transcription in pre-B cells (31). We find
that Pax5-binding in the vicinity of the Jκ–Cκ intron is dependent
on the presence of the Dm element and that the Pax5-binding
site contributes to the demethylating capabilities of the Dm ele-
ment. While this clearly cannot be the only Pax5-binding site, since
∆Dm pre-B cells maintain their full ability to rearrange the Igκ
locus, this site highlights the potency of this B cell identity protein
in one more area of B cell development.
It should be noted that the sequence of the Pax5-binding site
within the Dm element is conserved among rodents, but not in the
human-Igκ locus, though other aspects, such as the CpG-dense
region, are. This is not the only aspect which differs between the
human and murine counterparts of the Igκ locus. For example,
the Sis element, a transcriptional silencer which has been shown
to recruit the Igκ locus to the pericentromeric heterochromatin in
mice, is not conserved in the human locus (57). It stands to rea-
son that regulation of the human and murine Igκ loci may differ
somewhat, as the strongly biased usage of the κ versusλ chain seen
in mice (where 95% of mature B cells express the κ chain) is not
present in humans, which have a ratio of 60:40 of κ versus λ usage
(58). This could be due to differences in the RR of the human and
murine Igκ locus that may contribute to this phenomenon.
While the deletion of the Dm element did not, on its own,
affect the methylation status of the endogenous Igκ locus, nor the
relative amount of the deleted allele which underwent rearrange-
ment, we observed a decrease in the levels of SHM on Igκ alleles
lacking the Dm element. The role of the Dm element in facili-
tating SHM appears to be independent of the iEκ/MAR region,
since the combined deletion of the iEκ and MAR elements has no
perceptible effect on SHM (18). The lower level of SHM does not
appear to be the result of lower levels of Igκ transcription, since
deletion of the Dm element does not lower the levels of Igκ RNA
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observed in mature B cells. Deletion of the Dm element appears to
cause inefficient recruitment of the mutating machinery, but once
the machinery is in place, the mutation efficiency is similar to
the WT locus. The element may therefore function by efficiently
recruiting the mutation machinery to the locus, possibly by key
regulators such as Pax5 which are bound to the Dm element. Pax5
itself has a known role in SHM by activating the transcription of
the Aicda gene, encoding the AID protein, which is the deami-
nase responsible for SHM (59, 60). It may be that Pax5 plays more
than one role in SHM induction. The role of the Dm element
in SHM fits in well with its location, which is almost immedi-
ately adjacent to the Vκ–Jκ rearranged region which is the hotspot
for SHM.
In conclusion, we have characterized the Dm sequence as an
element that regulates the Igκ locus during different stages of
B cell development. The Dm is both a team player, cooperating
with the three characterized enhancers to demethylate the locus
for rearrangement, as well as an element that affects the locus in
its own right in allowing efficient SHM. This report adds to our
understanding of the complex regulation of the Igκ locus, which
undergoes many drastic changes during development and must be
fine-tuned for each developmental stage.
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